Use of evidence-based medicine (EBM) improves outcomes after acute coronary syndromes
(ACS), yet patients often discontinue prescribed therapies after discharge. Although such …

Purpose Little is known on the use of evidence‐based medications in patients with acute
myocardial infarction (AMI) across all ages. We undertook this study to describe the patterns …

Background The prescription of guideline-recommended medication for secondary
prevention after acute coronary syndrome has been suboptimal in the past. In the present …

Background Few studies have evaluated age-related predictors associated with the
underuse of medications in patients with coronary heart disease (CHD). The objective of this …

BACKGROUND After acute myocardial infarction (AMI), treatment with beta-blockers and
angiotensin-converting enzyme inhibitors (ACEI) is widely recognized as crucial to reduce …

Background—Acute coronary syndrome (ACS) patients in the highest risk categories are
least likely to receive evidence-based treatments (EBTs). We sought to determine why …

Background Although it has been well documented that aspirin, β-blockers, angiotensin-
converting enzyme (ACE) inhibitors, and lipid-lowering drugs are under-prescribed for …

Background Publication of population-based analyses of medication use after acute
myocardial infarction (AMI) could encourage the use of effective secondary prevention …

Importance Adherence to cardioprotective medication regimens in the year after
hospitalization for acute coronary syndrome (ACS) is poor. Objective To test a multifaceted …

Background The prescription of recommended medical therapies is a key factor to improve
prognosis after acute coronary syndromes (ACS). However, reasons for cardiovascular …